Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

26.22 +26.22 (+1048700.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
ARQT stock results show that Arcutis Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Peeling Back The Layers: Exploring Arcutis Biotherapeutics Through Analyst Insights ↗
 
Via Benzinga
News headline image
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Biotherapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
Evaluating Arcutis Biotherapeutics: Insights From 5 Financial Analysts ↗
 
Via Benzinga
News headline image
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
7 Biotech Stocks to Keep on Your Clinical Radar ↗
Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs. 
Via InvestorPlace
News headline image
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years ↗
FDA approved Arcutis Biotherapeutics' sNDA for Zoryve cream 0.15% for mild to moderate atopic dermatitis in patients aged six and older. Zoryve provides a steroid-free treatment option. Significant... 
Via Benzinga
News headline image
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Intapp, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
The 7 Best Under $10 Stocks to Buy in July 2024 ↗
We’re finding big opportunities in some of the best stocks under $10 a share. In fact, here are seven you may want to jump into now. 
Via InvestorPlace
News headline image
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Have $5-10? 7 Affordable Stocks That Are About to Breakout. ↗
These stocks are already showing gains this year, but they are all still affordable stocks ready to breakout. 
Via InvestorPlace
News headline image
Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
We are covering the biggest pre-market stock movers for Wednesday with all of the latest happenings worth watching this morning! 
Via InvestorPlace
News headline image
ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
ARQT stock results show that Arcutis Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Arcutis Biotherapeutics Stock Climbs After Blockbuster Q1 Results ↗
Arcutis Biotherapeutics reports its first-quarter financial results after the bell Tuesday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.